Spots Global Cancer Trial Database for recurrent uterine corpus sarcoma
Every month we try and update this database with for recurrent uterine corpus sarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer | NCT01168232 | Recurrent Uteri... Uterine Carcino... | Ixabepilone Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | NCT00025506 | Recurrent Uteri... Uterine Carcino... | Laboratory Biom... Thalidomide | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | NCT00031629 | Recurrent Uteri... Uterine Corpus ... | Docetaxel Filgrastim Gemcitabine Hyd... Pegfilgrastim | 18 Years - | GOG Foundation | |
| Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus | NCT00031629 | Recurrent Uteri... Uterine Corpus ... | Docetaxel Filgrastim Gemcitabine Hyd... Pegfilgrastim | 18 Years - | GOG Foundation | |
| Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer | NCT01098630 | Recurrent Cervi... Recurrent Uteri... Recurrent Uteri... Stage I Uterine... Stage I Uterine... Stage IA Cervic... Stage IB Cervic... Stage II Uterin... Stage II Uterin... Stage IIA Cervi... Stage IIB Cervi... Stage III Cervi... Stage III Uteri... Stage III Uteri... Stage IV Uterin... Stage IV Uterin... Stage IVA Cervi... Stage IVB Cervi... | Medical Chart R... Questionnaire A... | - | GOG Foundation | |
| Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | NCT01637961 | Recurrent Uteri... Uterine Corpus ... | Alisertib Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | NCT00025506 | Recurrent Uteri... Uterine Carcino... | Laboratory Biom... Thalidomide | - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma | NCT01012297 | Recurrent Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri... Uterine Corpus ... | Bevacizumab Docetaxel Filgrastim Gemcitabine Hyd... Pegfilgrastim Placebo | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer | NCT00114218 | Recurrent Uteri... Uterine Carcino... | Gemcitabine Hyd... Docetaxel | - | GOG Foundation | |
| Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | NCT01637961 | Recurrent Uteri... Uterine Corpus ... | Alisertib Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer | NCT01247571 | Recurrent Uteri... Uterine Carcino... | Pazopanib Hydro... | 18 Years - | National Cancer Institute (NCI) | |
| Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus | NCT00025220 | Recurrent Uteri... Uterine Corpus ... | Thalidomide Laboratory Biom... | - | National Cancer Institute (NCI) | |
| Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy | NCT01220609 | Recurrent Uteri... Uterine Corpus ... | Ixabepilone Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
